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ABSTRACT: This paper reports the first application of high-resolution 1H NMR spectroscopy to the plasma of five juveniles
with glycogen storage disease type 1a (GSD1a), permitting the characterisation of the plasma metabolic profile and the
identification of alterations relative to a set of control samples. The relaxation-weighted spectra allowed changes in low
molecular weight compounds to be detected more clearly, whereas diffusion-edited spectra were used to characterise the
plasma lipoprotein profile. Lowmolecular weight metabolites with altered levels in most patients were lactate, ketone bodies,
acetate, creatine/creatinine and glucose. One of the patients showed distinctively lower glucose levels and higher lactate and
ketone body contents, suggesting poorer metabolic control of the disease compared with other patients. In addition, a
metabolite tentatively identified as a-hydroxyisobutyrate was only detected in the spectra of GSD1a plasmas, representing,
therefore, a possible novel GSD1a biomarker. Total lipoprotein contents were higher in the plasma from GSD1a patients.
Furthermore, lower HDL and higher VLDLþLDL levels also characterised the plasma of these patients. Preliminary results
on principal component analysis of 1H NMR spectra allowed a clear separation between GSD1a and control plasmas. The
specificity of the changes observed to GSD1a is discussed, together with the recognised potential of NMR and pattern
recognition methods for aiding the diagnosis of GSD1a. Copyright # 2006 John Wiley & Sons, Ltd.
KEYWORDS: NMR; GSD; glycogen storage disease; plasma; lipoproteins; biomarker
INTRODUCTION
The understanding and diagnosis of many diseases rely
heavily on the metabolic profiling of biological fluids
such as urine and plasma, as their composition is
intimately related to the biochemical status of a living
organism and carries information about the biological
processes associated with pathological conditions. High-
resolution 1H NMR spectroscopy provides an overall
view of the proton-containing metabolites at submilli-
molar concentrations in a body fluid, requiring minimal
sample preparation and avoiding the use of extraction or
derivatization steps to investigate specific groups of
metabolites, as usually required by conventional meta-
bolic screening techniques. To date, a significant number
of studies have demonstrated the outstanding value of
NMR spectroscopy for characterising the composition of
biofluids and investigating their perturbed metabolic
profiles in different diseases, as recently reviewed by
Lindon and co-workers (1,2). Inborn errors of metabolism
are a class of diseases where NMR spectroscopy has been
shown to be particularly useful, as alterations in a wide
range of metabolites can be detected simultaneously
without making a priori assumptions about the metabolic
processes involved, thus allowing the identification of
possible biomarkers. Indeed, NMR has not only shown its
diagnostic value for known errors of metabolism (3–8), but
has also led to the discovery of new inborn errors (9–11).
Glycogen storage disease type 1a (GSD1a) is an
autosomal recessive disease in which gene expression of
glucose-6-phosphatase is absent. This deficiency impairs
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the ability of the liver to produce free glucose from both
glycogenolysis and gluconeogenesis, leading to severe
hypoglycaemia and excessive accumulation of glycogen
in the liver and kidneys, causing enlargement of both.
Secondary clinical manifestations include lactic acidosis,
hyperlipidaemia, hyperuricaemia and growth retardation
(12). In addition, without effective treatment, long-term
complications occur, namely hepatic adenomas, renal
dysfunction, osteoporosis and gout (13–15). Currently,
treatment of this disease concentrates on avoiding
hypoglycaemia by continuously providing a dietary
supply of glucose, either by frequent ingestion of
cornstarch during day and night or nocturnal intragastric
feeding (16–18). Good dietary management minimises
the metabolic abnormalities of the disease and decreases
the risk of long-term complications, hence the early
diagnosis and initiation of treatment coupled with
effective follow-up assessment of metabolic control are
important objectives. This is particularly relevant for
GSD1a patients since for reasons yet unknown,
metabolic and glycaemic control often improves in
adulthood to the extent that the frequency of carbo-
hydrate feeding can be substantially curtailed (19).
Possible mechanisms include the induction of extra-
hepatic glucose-6-phosphatase activity in peripheral
tissues such as skeletal muscle (20) or increased activity
of lysosomal acid a-glucosidase, which generates
glucose directly from glycogen (21). GSD1a is usually
suspected on the basis of a set of clinical and
biochemical features, the definitive diagnosis being
confirmed by a liver biopsy and enzyme assay or, more
recently, by mutation analysis (12). Therefore, the
development of rapid and minimally invasive diagnostic
methods continues to be a challenge.
In vivo localised 13C MRS of human liver has been
shown to be a fast and non-invasive tool for quantifying
hepatic glycogen content in patients with different types
of GSD (22,23) and in vivo 31P magnetic resonance
permitted the study of liver metabolism in GSD1a
patients (24). Other relevant NMR studies of GSD include
investigations of glucose carbon recycling by 13CNMR of
plasma using 13C-labelled glucose (25,26). However, to
our knowledge, there are no studies reporting the
metabolic profiling of this disease by NMR.
The present work is the first application of high-
resolution 1H NMR spectroscopy to the plasma of
children with GSD1a, aimed at characterising its
metabolic profile and looking for consistent alterations
relative to control plasma samples. In addition to standard
1D spectra, relaxation- and diffusion-edited experiments
were recorded in order to improve the detection of
changes in small metabolites and macromolecules,
respectively. Principal component analysis (PCA) was
applied to the spectra datasets as a means to validate the
findings from visual inspection of the spectra and to
identify the spectral features with larger variability
between controls and patients.
EXPERIMENTAL
Patients
Five juveniles with GSD1a [3M, 2F, age 14 6 years
(minimum 9, maximum 25 years); weight¼ 35 9 kg
(minimum 25, maximum 50 kg); labelled P1–P5] and five
healthy controls [1M, 4F, age 20 4 years (minimum 15,
maximum 25 years); weight¼ 53 13 kg (minimum 40,
maximum 71 kg); labelled C1–C5] were considered. The
uncertainty ranges indicated correspond to the standard
deviation intervals. Following informed consent, subjects
were enrolled into a study protocol approved by the
Pediatrics Hospital of Coimbra Ethics Committee.
GSD1a patients were maintained on cornstarch feeding
overnight whereas healthy controls had a meal at 20:00
the evening before the study and were fasted until the start
of the protocol at 08:00 the next day. At 08:00, 11:00 and
14:00, all subjects ingested 1g/kg body weight of
cornstarch dissolved in water to form a thin slurry. As
part of a parallel study, all subjects also took paracetamol
at 08:00 (10–15mg/kg) and phenylbutyric acid (5mg/kg)
plus [U-13C]glycerol (25–30mg/kg) at 14:00. These
reagents were all dissolved in the cornstarch meal and
were not expected to affect the results of the present work.
Indeed, ingested glycerol is quantitatively extracted from
the splanchnic circulation by the liver and is not expected
to perturb endogenous plasma glycerol levels and, in
addition, paracetamol, phenylbutyrate and their metab-
olites are rapidly cleared into the urine therefore not
contributing to the 1H NMR spectrum of plasma (data not
shown). Blood (10mL) was collected at 17:00, at which
point the study was finished.
Samples
Blood was collected by venipuncture and placed in vials
containing EDTA as an anticoagulant, except in one
control subject (C5), where a heparinised vial was used.
The plasma was separated immediately by centrifugation
(3000 g, 10min), frozen and stored at 20 8C until
NMR analysis. Typically, 200mL of each sample were
mixed with 400mL of aqueous saline (0.9% NaCl) and
centrifuged (8000 rpm, 5min). Owing to the small
volume available, one of the samples (C5) was prepared
with a higher dilution factor (100mL to 500mL saline). A
volume of 500mL was then transferred to an NMR tube
and 50mL of D2O were added.
NMR measurements
High-resolution NMR spectra of blood plasma were
recorded at 298K on a Bruker Avance DRX-500
spectrometer, operating at 500.13MHz for proton and
equipped with an actively shielded gradient unit with a
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maximum gradient strength output of 53.5G/cm.
Standard 1D 1H spectra were acquired using a 1D
NOESY pulse sequence (RD–908–t1–908–tm–908–
acquire) with a relaxation delay (RD) of 13s, a mixing
time (tm) of 100ms and a fixed t1 delay of 3ms. Water
suppression was achieved by presaturation of the water
signal during the relaxation delay and mixing time. Each
spectrum consisted of 128 free induction decays (FIDs)
collected into 32K complex data points with a spectral
width of 8012.82Hz and an acquisition time of 2.0 s.
Three to six replicate spectra were recorded for each
sample, for multivariate analysis. 1D relaxation-edited 1H
spectra were acquired (with no replicas) using the Carr–
Purcell–Meiboom–Gill (CPMG) pulse sequence (RD–
908–{t–1808–t}n–acquire) (27) with simple presaturation
of the water peak, a total spin–spin relaxation time (2nt)
of 200ms and a relaxation delay of 13 s. Typically, 256
FIDs were collected into 32K complex data points. 1D
diffusion-edited spectra were recorded (with no replicas)
using the bipolar pulse longitudinal eddy current delay
(BPPLED) pulse sequence (28). In order to attenuate the
signals from low molecular weight compounds without
affecting the lipoprotein signals, square gradients with a
duration of 2ms and a strength of 48.15G/cm were used,
together with a diffusion time of 200ms; 128 FIDs were
collected into 32K complex data points, using a 13s
relaxation delay. Prior to Fourier transformation, the FIDs
were zero-filled to 64K points and multiplied by an
exponential line-broadening function of 0.3Hz. The 1D
spectra were manually phased, the baseline corrected and
the chemical shifts referenced internally to the a-glucose
signal at d 5.23. Additionally, 2D TOCSY and HSQC
spectra were recorded for selected samples to aid spectral
assignment.
Principal component analysis (PCA)
For each set of spectra to which PCA was applied
(standard 1D, relaxation-edited and diffusion-edited), a
data matrix was built from d 0 to 6, excluding the water
region (d 4.5–5.0) and the segments containing EDTA-
related signals (d 2.53–2.58 and 3.06–3.18). All the
remaining data intensity values were used for the PCA.
Each spectrum was normalized by adjusting the total area
to unity. The calculations were performed using a
program co-developed in the University of Aveiro and
the Institut National Agronomique Paris-Grignon (29).
RESULTS
Figure 1(a) shows a standard 1D 1H spectrum of blood
plasma collected from a GSD patient. As typically
observed, this spectrum is dominated by the broad
resonances of lipoproteins and other plasma proteins such
as albumin, which mask the signals from low molecular
weight metabolites. Some degree of spectral editing can
be achieved by employing a CPMG pulse sequence in
order to attenuate or even eliminate resonances from
macromolecules (or bound small molecules) with shorter
T2 relaxation times (30,31). Indeed, the CPMG spectrum
[Figure 1(b)] gives a much clearer representation of small
metabolites, especially in the low-frequency (d 0–3) and
high-frequency (d 6–10) regions. Based on the literature
(1,30,31) and on the 2D spectra recorded, several low
molecular weight compounds such as amino acids
(e.g. valine, leucine, isoleucine, alanine, proline, histi-
dine, tyrosine), organic acids (e.g. lactate, acetate, citrate,
formate), acetone, creatine, creatinine and glucose have
been identified, as indicated in the figure caption. On the
other hand, the macromolecular profile can be visualized
without the sharp signals by utilizing the difference in
translational diffusion coefficients between macromol-
ecules and metabolites, an approach which is particularly
useful for allowing the direct study of plasma lipoproteins
(32–37). Figure 1(c) shows the diffusion-edited spectrum
obtained for the same plasma sample. Compared with the
standard 1D spectrum [Figure 1(a)], the peaks from fast-
diffusing, small metabolites have been strongly attenu-
ated, whereas the broad resonances corresponding to
slow-diffusing macromolecules are not affected. A
significant number of signals arise from the various
types of protons in the fatty acyl chains of lipoproteins,
the most prominent corresponding to the terminal methyl
protons (d 0.87) and the long-chain methylene protons
(d 1.27) [peaks 18 and 19, respectively, in Fig. 1(c)]. Other
parts of the lipoprotein molecules are observed through
the signals arising from the head groups (NþMe3) of
choline-containing phospholipids (peak 26). Signals
corresponding to the N-acetyl groups of glycoproteins
and the lysyl groups of albumin are also detected [peaks 8
and 25 in Fig. 1(c)].
Variations in plasma low molecular weight
metabolites
In order to look for qualitative or quantitative differences
in the low molecular weight metabolites present in the
plasma of GSD1a patients relative to control subjects, the
CPMG spectra of both groups were compared. For some
compounds with reduced spectral overlap, a semi-
quantitative analysis was carried out by integrating
selected signals and dividing their integrals by the total
spectral area to account for differences in sample dilution
(Fig. 2). This approach is based on the assumption that for
each compound there is no significant variation in the
proton T2 times between different samples, which seems
to be reasonable, since all samples were analysed under
the same conditions. Therefore, given the high degree of
spectral overlap in the standard 1D spectrum, integration
of the CPMG spectra is a possible alternative to obtain
semi-quantitative information, although it cannot be used
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for absolute metabolite quantification owing to selective
signal loss for compounds with different T2 relaxation
times.
The average lactate level is higher in patients than in
controls, although there is a significant intra-group
variation, especially within patients [Figure 2(a)]. The
plasma of patient P3 contains a markedly higher lactate
concentration, whereas in patient P5 the lactate content is
close to the average value found for the control group.
While the aggregate amount of ketone bodies is generally
higher in GSD patients, individual ketone bodies tend to
be less specific markers for GSD. For example, levels of
b-hydroxybutyrate and acetone for the GSD group are
similar to controls, with the exception of P3, who has high
Figure 1. 500MHz 1H NMR spectra of plasma from a patient with GSD1a: (a) standard 1D
spectrum; (b) 1D relaxation-edited (CPMG) spectrum; (c) 1D diffusion-edited spectrum.
Assignment: 1, valine; 2, leucine; 3, isoleucine; 4, b-hydroxybutyrate; 5, lactate; 6, alanine;
7, acetate; 8, N-acetyl groups of glycoproteins; 9, acetone; 10, proline; 11, citrate; 12,
creatine; 13, creatinine; 14, glucose; 15, tyrosine; 16, histidine; 17, formate; 18, lipid CH3;
19, lipid (CH2)n; 20, lipid CH2CH2CO; 21, lipid CH2CH2CH––CH; 22, lipid CH2CH––CH; 23,
lipid CH2CO; 24, lipid CH––CHCH2CH––CH; 25, CH2 lysyl (albumin); 26, N(CH3)3 choline in
phospholipids; 27, lipid CH––CH. The high-field inset in (b) shows the singlet tentatively
assigned to a-hydroxyisobutyrate
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concentrations of both metabolites [Fig. 2(b) and (c)].
Further, acetoacetate is present in all GSD patients with
the exception of P5, but is not found in any of the controls.
The level of acetate also shows great variation within
each subject group, but has a clearly higher average
concentration in GSD patients compared with control
subjects [Fig. 2(d)]. In addition, the CPMG spectra of
GSD patients show a signal at d 1.35, not detected in
control plasmas, which is possibly a singlet assignable to
a-hydroxyisobutyrate [inset in Fig. 1(b)]. This compound
has been detected previously by NMR in some spectra of
urine samples (1), but not, to our knowledge, in human
blood plasma.
Another difference between controls and patients,
detected in the CPMG spectra, concerns the relative
intensities of creatine (d 3.03 and 3.92) and creatinine
Figure 2. Representation of signal areas of some metabolites measured in the
CPMG spectra of controls (C1–C5) and GSD1a patients (P1–P5), where the vertical
bars represent average values: (a) lactate (d 1.32); (b) b-hydroxybutyrate (d 1.19);
(c) acetone (d 2.22); (d) acetate (d 1.91); (e) creatine (d 3.03)/creatinine (d 3.04); (f)
glucose (d 5.23)
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(d 3.04 and 4.05) signals (Fig. 3). These compounds show
varying proportions in the five control subjects, while
creatine predominates over creatinine in all GSD cases.
By deconvolution of the two signals at d 3.03 and 3.04,
arising from creatine and creatinine methyl groups,
respectively, the creatine/creatinine area ratio is found to
have an average value of 0.9 for controls and 3.6 for
patients [Fig. 2(e)]. However, the large dispersion within
patients should be noted once more.Whereas the creatine/
creatinine ratio of patient P2 is about 1.5, being close to
some of the control values, in patient P3 the signal area of
creatine is found to be more than five times higher than
that of creatinine.
In terms of glucose levels, spectral integration gives
higher average values in controls than in patients,
although there is considerable overlap between the
ranges found for the two groups [Fig. 2(f)]. The exception
is patient P3, who has much lower glucose than all other
samples.
Variations in plasma lipoproteins
In order to compare the levels of total lipoproteins
between subjects, spectral integration was performed on
diffusion-edited spectra, which are not affected by
overlap with signals from small metabolites and, there-
fore, permit more accurate semi-quantitative analysis
than standard 1D spectra. Obviously, the areas in
diffusion-edited spectra are not representative of the
proton stoichiometry, and hence cannot be used for
absolute quantification. Still, assuming that lipoproteins
have similar diffusion behaviour in all samples under the
experimental conditions used and, therefore, that their
NMR signals show comparable visibility in all spectra,
the overall changes in peak area relative to the spectral
noise level provide an indication of how concentration
levels differ between the different samples. Figure 4(a)
shows the area of the signal arising from (CH2)n protons
of the various lipoprotein fractions (d 1.24–1.27) divided
by the total spectral area to account for differences in
sample dilution. It is found that all GSD patients have
higher plasma lipoprotein levels than control subjects,
this difference being more noticeable for patient P3.
In addition to this difference in total quantity, the
diffusion-edited spectra show slight differences in the
qualitative profile, as illustrated in Fig. 5 for the signals
arising from the methyl (d 0.84–0.87) and methylene
(d 1.24–1.27) protons of fatty acyl groups of the lipid
components in lipoproteins. It is well described in the
literature that each of these resonances comprises a
superimposition of signals arising from different types of
lipoproteins in plasma (34,38). The three main lipoprotein
types, traditionally classified according to their density
and hence their size, are high-density lipoprotein (HDL),
low-density lipoprotein (LDL) and very low-density
lipoprotein (VLDL). They all consist of a lipid core of
triglycerides and cholesteryl esters inside a layer of
phospholipid, free cholesterol and apolipoproteins,
differing in the lipid and protein proportion. Owing to
their similar chemical composition, these fractions show
heavily overlapping signals, although there are small
differences in chemical shifts according to the size of the
lipoprotein particles. As shown in the spectra of
physically separated fractions (38,39), larger size
particles, namely VLDL complexes, give rise to methyl
and methylene group signals shifted to higher frequen-
cies. A first observation when comparing the spectra
shown in Fig. 5 is the similarity of profiles within patients
in contrast with the qualitative variations characterising
control spectra. Second, it is found that the lipoprotein
signals in all patients’ spectra have their maxima slightly
Figure 3. Expansion of the CPMG spectra of controls (C1–
C5) and GSD1a patients (P1–P5) showing the signals of
creatine (d 3.03) and creatinine (d 3.04)
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shifted to higher frequency relative to the spectra of most
control plasmas. In the case of the methylene resonance,
the spectra of all control plasmas except C4 show a more
prominent shoulder at d 1.23 relative to the main peak at
about d 1.27 which, according to previous NMR studies of
plasma lipoproteins (34,39), arise mainly from HDL and
LDLþVLDL, respectively. In the case of the methyl
peak, the contribution of the shoulder at d 0.83,
corresponding mainly to HDL, is also higher for controls
(except C4). Therefore, it may be suggested that the
proportion of HDL in control plasma is higher than that in
the plasma of GSD1a patients, although this hypothesis
needs further confirmation by quantification of the
individual lipoprotein fractions. Ultracentrifugation fol-
lowed by specific enzymatic assays is the standard
reference method for lipoprotein analysis, but it requires a
large amount of plasma, which was not available in the
present study. Alternative methods based on NMR
spectroscopy, namely liquid chromatography coupled
to NMR (LC–NMR) and 2D-DOSY NMR, are currently
being explored in our laboratory, aimed at quantifying the
lipoprotein main fractions in a new set of plasmas from
GSD1a patients, and this work will be reported in a
subsequent paper.
Regarding the total amount of unsaturated fatty acids,
there is no significant difference between controls and
GSD1a patients, as found by integration of the broad
signal at about d 5.3 arising from olefinic protons (CH––
CH) in fatty acyl chains [Fig. 4(b)]. However, a small shift
is noted for this signal between the spectra of controls
(d 5.28) and patients (d 5.30), as illustrated in Fig. 6(a) for
two representative cases, which is accompanied by a
higher intensity of the signal at d 2.74 [lipid CH––CH–
(CH2–CH––CH)n] in the spectra of GSD1a plasmas
compared with controls [Fig. 6(b)]. According to the
assignment of unsaturated fatty acids in lipids of tissues
and body fluids (40), these differences suggest a higher
proportion of polyunsaturated fatty acids (PUFA) and a
lower proportion of monounsaturated fatty acids (MUFA)
in the plasma of GSD1a patients.
PCA of 1H NMR spectra of plasma
Although the number of samples included in this study
was limited owing to the low incidence of the disease
[1/100 000 births (14)] and consequent small number of
patients at any one time, PCAwas applied to the dataset in
order to check the findings from the visual inspection of
the spectra and to determine the most important sources
of variability between controls and patients. The scores
scatter plot resulting from applying PCA to the standard
1D spectra (water and EDTA signals excluded) is shown
in Fig. 7(a). The good reproducibility of the standard 1D
spectra is visible in the results, as the scores correspond-
ing to replicate spectra of the same sample overlap. There
is a clear separation between control and GSD1a samples
along PC1, patient P3 showing the most negative scores,
and, therefore, the largest separation from the control
group. The PC1 loadings vector [Fig. 7(b)] shows the
spectral features responsible for this separation. Glucose
signals are positive in PC1 loadings, confirming the
higher average values in controls and the lower value in
patient P3, as observed by spectral integration. On the
other hand, strong negative loadings are found for the
signals of lactate (d 1.32 and 4.11), indicating elevated
levels of this metabolite in patients, especially in those
with the most negative PC1 scores. However, when the
segments including the lactate signals are removed from
the matrix used for PCA, a similar PC1 vs PC2 scores plot
is obtained (not shown), indicating that other compounds
also contribute strongly to the observed separation. In
Figure 4. Representation of signal areas measured in the diffusion-edited spectra
of controls (C1–C5) and GSD1a patients (P1–P5), where the vertical bars represent
average values: (a) lipoprotein (LP) methylene signal at d 1.24–1.27; (b) olefinic
protons in fatty acyl groups signal at d ca 5.3
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particular, the contributions of acetate (d 1.91) and
acetone (d 2.22) are enhanced, showing negative PC1
loadings and, therefore, higher levels in patients. These
results are in general agreement with the results of
spectral integration and were confirmed by PCA applied
to the relaxation-edited spectra (not shown). These same
PCA results highlighted the difference in the levels of
creatine and creatinine, as already detected by visual
comparison of the spectra.
Furthermore, the loadings in Fig. 7(b) suggest the
contribution of broad lipoprotein resonances to the
observed distribution of samples scores. In order to
investigate this further and evaluate the variability in the
macromolecule profile, PCA was also applied to the
diffusion-edited spectra. Again, a good separation
between control and GSD1a samples is seen along PC1
in the scores scatter plot of PC1 vs PC2 [Fig. 8(a)]. The
PC1 loadings [Fig. 8(b)] show positive values at d 0.83
and negative values at d 0.87 and 1.27. As argued in the
previous section based on the literature, the former
chemical shift is characteristic of HDL, whereas the 0.87
and 1.27 ppm signals arise mainly from LDLþVLDL.
Therefore, in agreement with the visual comparison of the
spectra, the PCA results suggest that GSD1a patients
show a lower proportion of HDL and a higher proportion
of LDLþVLDL relative to control subjects. In addition,
the signal at d 3.22, assigned to the methyl head groups of
choline-containing phospholipids, also shows clearly
positive loadings, together with the signal at d 0.83, which
supports the assignment of this resonance to HDL, since
phosphatidylcholine is known to be the most predominant
lipid in the HDL fraction (34). Finally, the PC1 loadings
in Fig. 8(b) show a split of the signal arising from lipid
olefinic protons, with positive values for d 5.28 and
negative values for d 5.30, which confirms the shift of this
signal to higher frequencies in the GSD plasma spectra
relative to control spectra, as already observed by visual
comparison of the spectra.
DISCUSSION
This paper reports the direct analysis of plasma from
GSD1a patients by 1H NMR spectroscopy, using
relaxation- and diffusion-edited experiments to detect
Figure 5. Expansion of the diffusion-edited spectra of con-
trols (C1–C5) and GSD1a patients (P1–P5) showing signals
from the methyl (d 0.84–0.87) and methylene (d 1.24–1.27)
protons of fatty acyl groups of lipoproteins. Each spectrum is
scaled to maximum peak intensity
Figure 6. Expansion of the diffusion-edited spectra of con-
trol C2 and patient P3 showing signals from (a) CH––CH (dca
5.3) and (b) CH––CH–CH2–CH––CH (d 2.65–2.80) of fatty acyl
groups
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changes in low molecular weight compounds and in
macromolecules, respectively.
The low molecular weight metabolites whose levels in
plasma were most different between GSD1a patients and
healthy controls were lactate, ketone bodies, acetate,
a-hydroxyisobutyrate, creatine/creatinine and glucose.
Elevated plasma lactate levels are a common feature of
GSD1a, reflecting the inability of systemic lactate to be
recycled into glucose via gluconeogenesis coupled with
high rates of glycolytic lactate production due to frequent
carbohydrate feeding. In the GSD1a patients enrolled in
this study, plasma lactate levels were generally high [see
Fig. 2(a)], particularly in the case of P3, where lactate
levels were about three times higher than in controls. This
patient, but not the others, also had significant levels of
lactate in urine (data not shown). In agreement, this is also
the patient with lower glucose levels than any other
samples. Persistent hyperlacticacidaemia has been
reported in several GSD1a cases despite dietary treatment
and represents a risk factor for long-term complications
such as renal dysfunction (41,42).
Two ketone bodies, b-hydroxybutyrate and acetone,
had markedly elevated levels in patient P3, but normal
levels in all other patients. On the other hand, acetoacetate
could only be detected in all patients but one (P5) and not
in the control plasmas. Ketone bodies are generated from
acetyl-CoA under conditions of hypoglycaemia and serve
as alternative oxidisable fuels for the brain and central
nervous system when there is insufficient glucose
available. The literature contains conflicting data about
ketone body concentrations in GSD1 patients. Decreased
ketone body levels have been reported (43), although a
different study did not confirm this finding (44).
Furthermore, in an acute GSD1b model in rats, the
plasma concentrations of b-hydroxybutyrate were iden-
tical with those in control rats (45). In the case of the
subjects included in this study, it may be suggested that
ketogenesis is increased in at least one of the patients, P3.
Elevated levels of acetate were also found in GSD1a
patients, although the range of acetate concentrations
within controls was also considerable. Other diseases
such as severe liver disease and severe acidosis have both
Figure 7. (a) Scores scatter plot of PC1 vs PC2 resulting
from PCA of standard 1D spectra of plasma from controls
(C1–C5) and GSD1a patients (P1–P5), the different spots for
each subject correspond to replicate spectra; (b) PC1 load-
ings vector
Figure 8. (a) Scores scatter plot of PC1 vs PC2 resulting
from PCA of 1D diffusion-edited spectra of plasma from
controls (C1–C5) and GSD1a patients (P1–P5); (b) PC1
loadings vector
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been associated with increased plasma acetate concen-
trations (46). Plasma acetate levels are also sensitive to
dietary state (47), since acetate is generated endogenously
by microbial fermentation of non-digestible carbo-
hydrates in the lower intestine.
An unexpected metabolite, tentatively identified as a-
hydroxyisobutyrate, has been detected in the spectra of
GSD1a plasmas and might represent a novel biomarker of
this disease. Unequivocal identification of this metabolite,
for instance using LC–NMR, as well as the determination
of its concentration are important tasks to be accom-
plished in the future. Another subtle difference between
control and patient spectra was found for the creatine/
creatinine ratio, which was higher in the plasma of most
GSD1a patients. This is due to relatively lower creatinine
levels in patients (with the exception of P2) compared
with the control group. This rules out any possible
correlation with the onset of renal dysfunction, known to
be accompanied by relatively high levels of blood
creatinine. Furthermore, it is probable that some
relationship exists between the average higher body
weights of the patients and the observed differences in
creatine/creatinine, a fact which hinders any GSD-
specific interpretation.
1H NMR spectroscopy, in particular 1D diffusion-
edited NMR, also allowed a preliminary study of the
plasma lipoprotein profile of GSD1a patients. A key
observation was the higher total lipoprotein contents
relative to control subjects. Hyperlipidaemia is a well-
known metabolic derangement of GSD1 and is not well
controlled by dietary therapy (48–52). Possible causes
include sharply increased rates of de novo lipogenesis
(51,52) and decreased rates of fat oxidation (48,50), both
of which are favoured by the high and frequent intake of
carbohydrate. These studies have reported increased
triglyceride and cholesterol concentrations, especially in
LDL and VLDL particles, which were found to be
increased not only in number but also in size. On the other
hand, HDL cholesterol and apolipoprotein A-1 concen-
trations are reported to be decreased. These statements are
in general agreement with the evidence found in this work
suggesting a lower proportion of HDL and a higher
proportion of LDLþVLDL in GSD1a patients relative to
control subjects. However, to confirm these findings, the
NMR results have to be explored further, a task which is
under way in our laboratory for a new set of GSD1a
plasma samples. In recent years, a significant effort has
been put into quantifying the different lipoprotein
fractions in human blood plasma, as disorders in
lipoprotein metabolism are critical to the development
of many diseases such as atherosclerosis, coronary heart
disease, liver dysfunction and cancer. NMR-based
methods show great potential in this respect and different
approaches have been reported. These include curve
fitting of the overlapped NMR bands based on known
positions and linewidths for individual lipoproteins
measured from purified fractions (38), multivariate
analysis of NMR spectra generally involving large
numbers of samples (37,53), 2D-DOSY NMR (34,37)
and LC–NMR (39).
Another finding suggested by the present study is the
different composition in fatty acids, namely in the
proportion of PUFA, which seems to be higher in GSD1a
patients, although the total amount of unsaturated fatty
acids (poly- and monounsaturated) seems to be similar for
controls and patients. Since this may be related to the
oxidizability of lipoproteins, it is important to investigate
this point further through a fuller characterisation of the
fatty acids present.
A clear separation between GSD1a and control
plasmas was achieved by applying PCA to either standard
1D, relaxation-edited or diffusion-edited spectra, showing
that the distinctive metabolic features of the disease arise
both from plasma small metabolites and lipoproteins.
Lactate and glucose were the low molecular weight
metabolites with the highest variability between controls
and patients. Other compounds contributing to the
separation of the two groups, especially highlighted by
PCA of the relaxation-edited spectra, were acetate,
acetone and creatine/creatinine. Furthermore, PCA of
standard 1D spectra suggested the contribution of
lipoprotein signals for the observed distribution
of samples. Indeed, this could be confirmed by PCA of
diffusion-edited spectra, which resulted in a clear
separation between healthy controls and GSD1a patients
due to the higher relative LDLþVLDL content and lower
HDL content in the latter. Therefore, in spite of the
limited number of samples available for this study, these
results show the promising diagnostic value of the
application of pattern recognition techniques to the 1H
NMR spectra of plasma from children suspected to have
an inborn error of metabolism with the clinical symptoms
of GSD1a.
In conclusion, this work demonstrates the significant
value of 1H NMR spectroscopy as a rapid and non-
invasive method to (a) find GSD biomarkers, knowledge
of which may aid in designing new disease diagnosis and
tracking methods, (b) contribute with new biochemical
information about the disease and (c) form the basis of
pattern recognition models to aid rapid and objective
GSD diagnosis. The specificity of the changes observed to
GSD1a is not fully known, at this stage. However, the
detection of a new indicator peak (possibly arising from
a-hydroxyisobutyrate) and particular changes in lipopro-
tein composition, together with the simultaneous changes
in lactate, glucose acetate and ketone bodies, should start
to form a picture of increasing specificity for GSD
diagnosis. The work described here is currently being
pursued along several parallel lines, namely the detailed
characterisation of the nature of lipoproteins and new
biomarkers and their relation to the disease and the
building of NMR-based models allowing rapid diagnosis
of the disease. The latter require a larger number of
samples compared with those shown here and will
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therefore require sample collection during long periods of
time, owing to the low incidence of the disease.
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